Idelalisib
- Generic Name
- Idelalisib
- Brand Names
- Zydelig
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18FN7O
- CAS Number
- 870281-82-6
- Unique Ingredient Identifier
- YG57I8T5M0
- Background
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituxi...
- Indication
用于治疗：复发慢性淋巴细胞性白血病(CLL)，与利妥昔单抗联用，在由于其他共患病将考虑对单独利妥昔单抗适当治疗患者。复发滤泡B-细胞非霍奇金淋巴瘤(FL)接受至少2次既往全身治疗患者。复发性小淋巴细胞淋巴瘤(SLL)曾至少接受2次既往全身治疗患者。
- Associated Conditions
- Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed follicular B-cell non-Hodgkin's lymphoma
- Associated Therapies
- -
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6
- Registration Number
- NCT02242045
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT02136511
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇮🇹Ospedale San Raffaele, Milano, Italy
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT02135133
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
- Conditions
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 102
- Registration Number
- NCT02044822
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Illinois Cancer Specialists, Niles, Illinois, United States
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 57
- Registration Number
- NCT01980875
- Locations
- 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
🇫🇷Centre Hospitalier de Perpignan, Perpignan Cedex 9, France
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 311
- Registration Number
- NCT01980888
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇨🇦Cancercare Manitoba - Maccharles Unit, Winnipeg, Manitoba, Canada
🇺🇸Franciscan Physician Network Oncology & Hematology, Indianapolis, Indiana, United States
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 106
- Registration Number
- NCT01838434
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 66
- Registration Number
- NCT01796470
- Locations
- 🇺🇸
University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 295
- Registration Number
- NCT01732913
- Locations
- 🇺🇸
Cancer Center of Santa Barbara, Santa Barbara, California, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸Saint Jude Heritage Healthcare, Fullerton, California, United States
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 475
- Registration Number
- NCT01732926
- Locations
- 🇨🇦
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
🇮🇹Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.